Raltitrexed
Child-Pugh Class A
Stanford UniversitySmall moleculePhase 3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Child-Pugh Class A cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Stanford University | Phase 3 | BB |
Idarubicine Stanford University | Phase 3 | BB |
Inno-206 Stanford University | Phase 3 | BB |
Ethiodized Oil Stanford University | Phase 3 | B |
Pembrolizumab Roswell Park Cancer Institute | Phase 1/2 | CCC |
Cyclophosphamide Roswell Park Cancer Institute | Phase 1/2 | CCC |
Epirubicin Roswell Park Cancer Institute | Phase 1/2 | CCC |
Sorafenib Roswell Park Cancer Institute | Phase 1/2 | CCC |
Same molecule, other indications
Raltitrexed is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →